## Edgar Filing: PROGENICS PHARMACEUTICALS INC - Form 8-K

PROGENICS PHARMACEUTICALS INC Form 8-K November 12, 2003

> SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

> > FORM 8-K CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) November 10, 2003

Delaware	000-23143	13-3379479
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)

777 Old Saw Mill River Road, Tarrytown, New York 10591 (Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code (914) 789-2800

(Former name or former address, if changed since last report.)

Item 9. Regulation FD Disclosure.

On November 10, 2003, the PSMA Development Company LLC, a joint venture of Progenics Pharmaceuticals, Inc. and Cytogen Corporation, announced publication of new findings on antibody and vaccine therapies that target prostate-specific membrane antigen (PSMA). A copy of the press release is attached as Exhibit 99.1.

The information furnished pursuant to Item 9 in this Form 8-K shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section, unless we specifically incorporate it by reference in a document filed under the Securities Act of 1933 or the Securities Exchange Act of 1934. We undertake no duty or obligation to publicly update or revise the information furnished

1

## Edgar Filing: PROGENICS PHARMACEUTICALS INC - Form 8-K

pursuant to Item 9 in this Form 8-K.

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PROGENICS PHARMACEUTICALS, INC.

By: /s/ PHILIP K. YACHMETZ Philip K. Yachmetz Vice President, General Counsel and Secretary

Date: November 12, 2003